The Free Fatty Acid Receptor 4 pipeline drugs market research report outlays comprehensive information on the Free Fatty Acid Receptor 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Free Fatty Acid Receptor 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Metabolic Disorders, and Undisclosed which include the indications Type 2 Diabetes, Diabetes, and Unspecified. It also reviews key players involved in Free Fatty Acid Receptor 4 targeted therapeutics development with respective active and dormant or discontinued products.
The Free Fatty Acid Receptor 4 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 1, 3, and 1 respectively.
Free Fatty Acid Receptor 4 overview
Free Fatty Acid Receptor 4 is a G protein-coupled receptor (GPR) encoded by FFAR4 gene. It acts as receptor for medium and long-chain free fatty acids (FFAs). It acts as a receptor for omega-3 fatty acids and mediates robust anti-inflammatory effects, particularly in macrophages and fat cells. The anti-inflammatory effects involve inhibition of TAK1 through a beta-arrestin 2 (ARRB2)/TAB1-dependent effect, but independent of the G (q)/G (11)-coupled pathway. It mediates potent insulin sensitizing and antidiabetic effects by repressing macrophage-induced tissue inflammation. It mediates the taste of fatty acids.
For a complete picture of Free Fatty Acid Receptor 4’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
